

SUPPLEMENTAL FILE 1.
Praveen et al.

Table of Contents

SUPPLEMENTARY APPENDIX:..... 2

SUPPLEMENTARY FIGURES..... 6

SUPPLEMENTARY FIGURE 1..... 6

SUPPLEMENTARY FIGURE 2..... 7

SUPPLEMENTARY FIGURE 3..... 8

SUPPLEMENTARY FIGURE 4..... 9

SUPPLEMENTARY NOTE 10

SUPPLEMENTARY METHODS..... 10

1 [Supplementary Appendix:](#)

2

3 **Regeneron Genetics Center Banner Author List and Contribution Statements**

4 All authors/contributors are listed in alphabetical order.

5 RGC Management and Leadership Team

6 Goncalo Abecasis, Aris Baras, Michael Cantor, Giovanni Coppola, Andrew Deubler, Aris
7 Economides, Luca A. Lotta, John D. Overton, Jeffrey G. Reid, Alan Shuldiner, Katia Karalis
8 and Katherine Siminovitch

9 Contribution: All authors contributed to securing funding, study design and oversight. All authors
10 reviewed the final version of the manuscript.

11 Sequencing and Lab Operations

12 Christina Beechert, Caitlin Forsythe, Erin D. Fuller, Zhenhua Gu, Michael Lattari, Alexander
13 Lopez, John D. Overton, Thomas D. Schleicher, Maria Sotiropoulos Padilla, Louis Widom, Sarah
14 E. Wolf, Manasi Pradhan, Kia Manoochehri, Ricardo H. Ulloa.

15 Contribution: C.B., C.F., A.L., and J.D.O. performed and are responsible for sample genotyping.
16 C.B, C.F., E.D.F., M.L., M.S.P., L.W., S.E.W., A.L., and J.D.O. performed and are responsible
17 for exome sequencing. T.D.S., Z.G., A.L., and J.D.O. conceived and are responsible for laboratory
18 automation. M.S.P., K.M., R.U., and J.D.O are responsible for sample tracking and the library
19 information management system.

20 Genome Informatics

21 Xiaodong Bai, Suganthi Balasubramanian, Boris Boutkov, Gisu Eom, Lukas Habegger, Alicia
22 Hawes, Shareef Khalid, Olga Krasheninina, Rouel Lanche, Adam J. Mansfield, Evan K. Maxwell,

23 Mona Nafde, Sean O’Keeffe, Max Orelus, Razvan Panea, Tommy Polanco, Ayesha Rasool,
24 Jeffrey G. Reid, William Salerno, Jeffrey C. Staples

25 Contribution: X.B., A.H., O.K., A.M., S.O., R.P., T.P., A.R., W.S. and J.G.R. performed and are
26 responsible for the compute logistics, analysis and infrastructure needed to produce exome and
27 genotype data. G.E., M.O., M.N. and J.G.R. provided compute infrastructure development and
28 operational support. S.B., S.K., and J.G.R. provide variant and gene annotations and their
29 functional interpretation of variants. E.M., J.S., R.L., B.B., A.B., L.H., J.G.R. conceived and are
30 responsible for creating, developing, and deploying analysis platforms and computational methods
31 for analyzing genomic data.

32 Clinical Informatics:

33 Nilanjana Banerjee, Michael Cantor, Dadong Li, Deepika Sharma, Ashish Yadav

34 Contribution: All authors contributed to the clinical informatics of the project

35 Translational and Analytical Genetics:

36 Alessandro Di Gioia, Sahar Gelfman

37 Contribution: All authors contributed to the analysis of the project.

38 Research Program Management

39 Esteban Chen, Marcus B. Jones, Jason Mighty, Michelle G. LeBlanc and Lyndon J. Mitnaul

40 Contribution: All authors contributed to the management and coordination of all research
41 activities, planning and execution. All authors contributed to the review process for the final
42 version of the manuscript.

43

44

45

46 **GHS DiscovEHR banner authors**

47 Lance J. Adams, Jackie Blank, Dale Bodian, Derek Boris, Adam Buchanan, David J. Carey, Ryan
48 D. Colonie, F. Daniel Davis, Dustin N. Hartzel, Melissa Kelly, H. Lester Kirchner, Joseph B.
49 Leader, David H. Ledbetter, Ph.D., J. Neil Manus, Christa L. Martin, Raghu P. Metpally, Michelle
50 Meyer, Tooraj Mirshahi, Matthew Oetjens, Thomas Nate Person, Christopher Still, Natasha
51 Strande, Amy Sturm, Jen Wagner, Marc Williams

52

53 **Decibel-REGN Hearing Loss Collaboration Banner Authors**

54 All authors/contributors are listed in alphabetical order.

55 Collaboration Core Team

56 Joe Burns¹, Giovanni Coppola², Meghan Drummond-Samuelson³, Aris Economides^{2,3}, David
57 Friendewey³, Scott Gallagher¹, John Lee¹, John Keilty¹, Christos Kyratsous³, Lynn Macdonald³,
58 Adam T Palermo¹, Kavita Praveen², Leah Sabin³, Jonathon Whitton¹, Brian Zambrowicz³

59

60 Contribution: Authors helped frame research questions and contributed to the discussion and
61 review of data and results. Review and feedback on manuscript.

62

63 Program Management & Alliance Management

64 Sarah Deng³, Geoff Horwitz¹, Alejandra K. King³, Jung H Sung³

65

66 Contribution: Contributed to the management and coordination of discussions.


67

68 Affiliations:

- 69 1. Decibel Therapeutics, Boston, MA USA
- 70 2. Regeneron Genetics Center, Tarrytown, NY USA
- 71 3. Regeneron Pharmaceuticals, Tarrytown, NY USA

72 SUPPLEMENTARY FIGURES

73 Supplementary Figure 1.



74

75

76 **Supplementary Figure 1: Q-Q plots for common and rare single variant and gene burden associations in UKB, GHS,**

77 **MALMO, SINAI and FinnGen.**

78 [Supplementary Figure 2.](#)


79 **[See Supplemental File 2 for Supplementary Figure 2: Regional plots for novel common**
80 **(MAF \geq 1%) loci identified in hearing loss meta-analysis and forest plots corresponding to**
81 **the index variant at each novel locus (panels A-R, 9 pages)]**

82

83

84 Supplementary Figure 3.

85



86

87

88

89 **Supplementary Figure 3: Heritability enrichments from stratified LD score regression**

90 **analysis.** Total SNP heritability for seven functional categories, each further stratified by MAF

91 into a common variant (CV, $MAF \geq 0.05$) and low-frequency variant (LFV, $0.001 \leq MAF < 0.05$)

92 bin, was estimated and enrichments for these categories was calculated (proportion heritability /

93 proportion variants). Plotted are the resulting enrichments (common variant bins shown as solid


94 circles and low-frequency variant bins as open triangles) with standard errors. Significant

95 enrichments and depletions are denoted by asterisks (Bonferroni-corrected $p < 0.05 = *$; $p < 0.01 =$

96 $**$; $p < 0.001 = ***$)

97 Supplementary Figure 4.

98



99

100

101 **Supplementary Figure 4: KLHDC7b is expressed in tissue within the temporal bone.** RNA

102 was extracted from different organs, and qPCR was performed using a primer/probe combination

103 for KLHDC7b, and one for Droscha as a housekeeping control. Data for each organ was normalized

104 to the housekeeping control and then normalized to liver expression. Expression in cochlea and

105 brain were not significantly different from expression in liver, which was relatively high. RQ =

106 relative quantification compared to liver (see methods).

107

108

109 SUPPLEMENTARY NOTE

110

111 [Supplementary Methods](#)

112

113 **Phenotype definition:**

114 Hearing loss in GHS, MALMO and SINAI was defined using ICD-10 codes: cases were
115 individuals who had (1) a problem-list entry of the ICD-10 diagnosis code (H903-H908, H911,
116 H919), (2) an inpatient hospitalization-discharge ICD-10 diagnosis code, or (3) an encounter ICD-
117 10 diagnosis code entered for 2 separate outpatient visits on separate calendar days. Controls were
118 individuals without any of the criteria for case definition. Individuals were excluded if they had
119 the relevant ICD-10 code associated with only one outpatient encounter. We also excluded from
120 controls any individuals who were cases for ICD-10 Q16 (congenital malformations of ear causing
121 hearing impairment) or ICD-10 H931 (tinnitus).

122 In UKB, hearing loss was defined using ICD-10 codes and self-reports based on two
123 questions: “Do you have any difficulty with your hearing?” (Field: 2247) and “Do you find it
124 difficult to follow a conversation if there is background noise (such as TV, radio, children
125 playing)?” (Field: 2257). Self-reported cases were individuals who (1) answered ‘yes’ to both
126 questions or (2) were completely deaf or (3) were a case for any of the following ICD-10 codes:
127 H903-H908, H911, H919. Phenotype definition of ICD10-based cases required one or more of the
128 following: a) ≥ 1 diagnosis in inpatient Health Episode Statistics (HES) records, b) a cause-of-
129 death diagnosis in death registry, c) ≥ 2 diagnoses in outpatient data (READ codes mapped to
130 ICD10). ICD-based controls were individuals who did not meet the case criteria, and were not cases
131 for ICD-10 Q16 and ICD-10 H931. To obtain the overall cases in the analysis, self-reported and
132 ICD-based cases were combined. Controls for the overall analysis were defined as individuals who
133 (1) answered ‘No’ to both self-report hearing loss questions and, (2) did not report that they were

134 deaf and (3) did not meet the criteria for ICD-based case definition and (4) did not have tinnitus
135 based on ICD-10 (H931) or self-reported tinnitus (Field ID: 4803, 4814 and self-reported from
136 verbal interview).

137

138 **Genotyping**

139 For SINAI and MALMO, DNA from participants was genotyped on the Global Screening
140 Array (GSA), and for GHS genotyping was done on either the Illumina OmniExpress Exome
141 (OMNI) or GSA. These cohorts were imputed to the TOPMed (GHS) or the HRC (MALMO,
142 SINAI) reference panels (stratified by array for GHS) using the University of Michigan Imputation
143 Server or the TOPMed Imputation Server (URLs). Prior to imputation, we retained variants that
144 had a MAF $\geq 0.1\%$, missingness $< 1\%$ and HWE $P > 10^{-15}$. Following imputation for GHS, data
145 from the OMNI and GSA datasets were merged for subsequent association analyses, which
146 included an OMNI/GSA batch covariate in addition to other covariates described below. UKB
147 DNA samples were genotyped as described previously¹ using the Applied Biosystems UK
148 BiLEVE Axiom Array (N=49,950) or the closely related Applied Biosystems UK Biobank Axiom
149 Array (N=438,427). Genotype data for variants not included in the arrays were imputed using three
150 reference panels (Haplotype Reference Consortium, UK10K and 1000 Genomes Project phase 3)
151 as described previously¹. FinnGen data were derived from a custom Axiom array and imputed into
152 the FinnGen SISu v3 reference panel (URLs).

153

154 **Exome sequencing**

155 High coverage whole exome sequencing was performed at the Regeneron Genetics
156 Center as previously described^{2,3}. NimbleGen probes (VCRome) or a modified version of
157 the xGen design from Integrated DNA Technologies (IDT) were used for target sequence capture,

158 and sequencing was performed using 75 bp paired-end reads on Illumina v4 HiSeq 2500
159 or NovaSeq instruments to a coverage depth greater than 20x at at least 85% of targeted bases in
160 96% of VCRome samples, and at least 90% of targeted bases in 99% of IDT samples. Sequence
161 read alignment and variant calling was based on the GRCh38 Human Genome reference sequence.
162 Ensembl v85 gene definitions were used to determine variants' functional impacts. Predicted LOF
163 genetic variants included (a) insertions or deletions resulting in a
164 frameshift, (b) insertions, deletions or single nucleotide variants resulting in the introduction of a
165 premature stop codon or in the loss of the transcription start site or stop site, and (c) variants in
166 donor or acceptor splice sites. Missense variants were classified for likely functional impact
167 according to the number of *in silico* prediction algorithms that predicted deleteriousness using
168 SIFT, Polyphen2_HDIV and Polyphen2_HVAR, LRT and MutationTaster. We aggregated rare
169 variants for gene burden testing as previously described⁴. Briefly, rare variants were collapsed by
170 gene region, such that individuals who are homozygous reference for all variants are considered
171 homozygous reference, heterozygous carriers of any aggregated variant are considered
172 heterozygous, and only minor allele homozygotes for an aggregated variant are considered as
173 minor allele homozygotes. Genotypes were not phased to consider compound heterozygotes in
174 burden testing. For each gene, we considered four categories of aggregates: a strict burden of rare
175 pLOFs and three more permissive burden of rare pLOFs and missense variants. The missense
176 variants in the burden aggregates were defined as 'strict deleterious missense' if predicted
177 deleterious by 5/5 prediction algorithms (SIFT, Polyphen2_HDIV, Polyphen2_HVAR, LRT,
178 MutationTaster), and 'deleterious missense' if predicted deleterious by at least 1/5⁴. For each of
179 these groups, we considered five separate burden masks per gene, based on the frequency of the
180 alternative allele of the variants that were screened in that group: $MAF \leq 1\%$, $MAF \leq 0.1\%$, MAF

181 $\leq 0.01\%$, $MAF \leq 0.001\%$, and singletons only. For the purposes of gene burden testing, the
182 singleton mask includes minor allele homozygotes if no other variant carriers are observed in the
183 dataset. We conducted further QC of associated variants *post-hoc*, based on mappability statistics
184 from read alignment.

185

186 **Genetic association analyses**

187 Association analyses in each study were performed using the Firth logistic mixed model
188 regression test implemented in REGENIE⁵. We included in step 1 of REGENIE (i.e. prediction of
189 individual trait values based on the genetic data) directly genotyped variants with a minor allele
190 frequency (MAF) $> 1\%$, $< 10\%$ missingness, Hardy-Weinberg equilibrium test $P > 10^{-15}$ and
191 linkage-disequilibrium (LD) pruning (1000 variant windows, 100 variant sliding windows and r^2
192 < 0.9). The association model used in step 2 of REGENIE included as covariates (i) age, age², sex,
193 age-by-sex and age²-by-sex; (ii) 10 ancestry-informative principal components (PCs) derived from
194 the analysis of a set of LD-pruned (50 variant windows, 5 variant sliding windows and $r^2 < 0.5$)
195 common variants from the array (imputed for the GHS study) data generated separately for each
196 ancestry; (iii) an indicator for exome sequencing batch (GHS: three batches; UKB: six batches);
197 and (iv) 20 PCs derived from the analysis of exome variants with minor allele count ≤ 20 and MAF
198 $< 1\%$ also generated separately for each ancestry.

199 We determined continental ancestries by projecting each sample onto reference principal
200 components calculated from the HapMap3 reference panel. Briefly, we merged our samples with
201 HapMap3 samples and kept only SNPs in common between the two datasets. We further excluded
202 SNPs with $MAF < 10\%$, genotype missingness $> 5\%$ or Hardy-Weinberg Equilibrium test $P < 10^{-5}$.
203 We calculated PCs for the HapMap3 samples and projected each of our samples onto those PCs.
204 To assign a continental ancestry group to each non-HapMap3 sample, we trained a kernel density

205 estimator (KDE) using the HapMap3 PCs and used the KDEs to calculate the likelihood of a given
206 sample belonging to each of the five continental ancestry groups. When the likelihood for a given
207 ancestry group was > 0.3 , the sample was assigned to that ancestry group. When two ancestry
208 groups had a likelihood > 0.3 , we arbitrarily assigned AFR over EUR, Admixed American (AMR)
209 over EUR, AMR over East Asian (EAS), South Asian (SAS) over EUR, and AMR over AFR.
210 Samples were excluded from analysis if no ancestry likelihoods were > 0.3 , or if more than three
211 ancestry likelihoods were > 0.3 . Results were subsequently meta-analyzed across studies and
212 ancestries using an inverse variance-weighted fixed-effects meta-analysis using an inverse
213 variance-weighted model in METAL⁶.

214

215 **Finemapping and follow-on genetic analyses**

216 LD score (LDSC) regression⁷ was used to assess inflation (LDSC intercept) in our
217 accounting for polygenic signal. We used LD scores calculated using genotyped or imputed
218 variants INFO >0.3 and MAF $>0.5\%$ from 10,000 randomly chosen subjects from UKB, and
219 restricted our analysis to HapMap3 variants.

220 We defined previously associated loci by their index variants reported in previous hearing
221 loss GWAS, and excluded 1 Mb regions surrounding them in the identification of novel loci in our
222 analysis. We defined genome-wide significant loci in our analysis by linkage disequilibrium ($r^2 >$
223 0.1) with lead variants.

224 Forward stepwise conditional analyses were carried out in every locus with GCTA-COJO
225 using summary statistics and a UK Biobank subsample LD reference panel. Independent
226 associations were determined using a joint P-value threshold of 1×10^{-5} and r^2 cutoff of 0.9.

227 Bayesian causal variant inference was conducted in available individual level data using
228 FINEMAP⁸.

229 Rare variant association analyses conditional on the common variant signal were carried
230 out for four loci with both common ($MAF \geq 0.01$) and single rare variant ($MAF < 0.01$) genome-
231 wide significant signals. For these loci, the dosages for variants representing the common variant
232 signal were included as covariates in REGENIE logistic regression. The specific variants that best
233 captured the common variant signal were ascertained through fine mapping analyses (FINEMAP
234 80% credible sets when available, or GCTA-COJO-identified independent [$r^2 < 0.9$] significant
235 [joint P-value $< 1 \times 10^{-4}$] variants). Burden analyses conditional on rare variants were carried out
236 for five genes with significant single rare variants in addition to their burden associations. For
237 these genes, conditional burden association statistics were obtained through inclusion of dosages
238 for the top (most significant) single rare variant in each gene. Conditional analyses were performed
239 for each cohort using REGENIE's Firth-corrected logistic regression and the resulting summary
240 statistics were meta-analyzed as described above.

241 Assessment of heterozygous effects used association analyses excluding homozygotes as
242 well as individuals potentially carrying compound heterozygous mutations (CHMs) called as
243 follows. Available unphased genotype array data and genetically inferred pedigree structures
244 determined by PRIMUS⁹ were used to create a phased genetic scaffold with the program
245 MakeScaffold. The scaffold and the unphased exome data were then provided to SHAPEIT^{4,10}
246 to generate phased exome variant calls. We then identified pairs of exome sequenced variants
247 ($MAF < 2\%$ and $MAC > 1$) within the same person and gene as potential CHMs (pCHM), and
248 determined them to be in cis, trans or unknown based on the phased exome data. Trans or
249 unknown-phase pCHMs were excluded.

250 Power curves were generated by specifying risk allele frequency (RAF), ranging from
251 1×10^{-6} to 1, and the numbers of cases and controls in our meta-analysis, and then determining
252 which genotype relative risk (GRR) values provide 80 and 50 percent power given the risk allele
253 frequency. z -score non-centrality parameters (NCP, i.e. expected values for Wald association test
254 statistics) for a case-control study was obtained following Zaitlen et. al.¹¹, power was obtained
255 using the `pnorm(u=NCP)` and `qnorm()` R functions, and GRRs for 50 and 80% power curves
256 given RAFs were estimated numerically.

257 Heritability derived from variants in specific functional categories and minor allele
258 frequency bins (in an approach similar to stratified LD score regression) was estimated using
259 partitioned LD score regression (LDSC) of hearing loss association statistics on LD scores. In
260 order to capture LD from both low-frequency and common variants, a reference panel (N = 10,000
261 samples) generated from the merging of UK Biobank (European-ancestry) imputed and exome
262 data was used. Reference panel variants were annotated using an internal pipeline and LD scores
263 with respect to seven functional categories (coding-synonymous, coding-nonsynonymous, 5-
264 prime-UTR, 3-prime-UTR, splice site, intronic, and intergenic), each split into a common (MAF
265 > 0.05) and low-frequency ($0.001 < \text{MAF} \leq 0.05$) variant bin, were calculated. Variants used to
266 calculate LD scores were filtered for false positives identified through support vector machine
267 learning of QC metrics, and both reference panel variants and summary statistics were restricted
268 to those with $\text{MAF} > 0.001$. Since our categories have a very small degree of overlap, with
269 approximately 0.01 percent of variants falling into more than one category, reported per-category
270 enrichment results were taken from the .results file (supplementary table 11) provided by LDSC
271 when using the `-overlap-annot` flag. As LDSC does not provide per-category h^2 estimates when
272 using this flag, however, we used per-category heritability estimates taken from the .log file from

273 non-overlap-annot runs to calculate h^2_{CV} and h^2_{LFV} each as the sum of the relevant common and
274 low-frequency variant category heritabilities.

275 For genes overlapping genome-wide significant hearing loss loci, coloc²¹² was used to
276 assess evidence for co-localization between our hearing loss GWAS and GTEx (release v8) eQTL
277 derived from 48 tissues (URLs). GWAS and eQTL summary statistics for all common (MAF >
278 0.01) variants within each gene's cis-region were used as input to coloc2, which then estimates
279 posterior probabilities for five hypotheses (H_0 , no association; H_1 , GWAS association only; H_2 ,
280 eQTL association only; H_3 , both but not co-localized; H_4 , both and co-localized) given the
281 association statistics and prior probabilities estimated from the observed data. Genes with posterior
282 probability of $H_4 \geq 0.5$ were determined as having evidence for co-localization.

283

284 **Single-Cell RNA Sequencing and Analysis**

285 Cochlea and utricles from C57BL/6 mice at post-natal day 7 were micro-dissected and
286 dissociated via incubation in 0.05% trypsin at 37°C for 20 - 30 min. Four volumes of 5% FBS in
287 DMEM/F12 with a final concentration of DNase (LK003170) greater than or equal to 100 Kunitz
288 per mL was added to inactivate any remaining trypsin. The tissues were then triturated 20 times
289 and passed through a 40- μ m strainer to eliminate residual aggregates / clumps of cells. Cells were
290 counted then resuspended in 0.04% BSA in PBS at a concentration of 200 cells / μ L.

291 Single cells suspended in PBS with 0.04% BSA were loaded on a Chromium Single Cell
292 Instrument (10xGenomics). RNAseq libraries were prepared using the Chromium Single Cell
293 3'Library, Gel Beads & Multiplex Kit (10x Genomics). Paired-end sequencing was performed on
294 an Illumina NextSeq 500 (Read 1 26-bp for unique molecular identifier, UMI, and cell barcode, 8-
295 bp i7 sample index, 0-bp i5, and Read 2 55-bp transcript read). Cell Ranger Single-Cell Software

296 Suite (10X Genomics, v2.0.0) was used to perform sample de-multiplexing, alignment, filtering,
297 and UMI counting. The Mouse MM10 Genome assembly and UCSC gene models were used for
298 alignment. CellRanger output was processed using Seurat V3.2 (URLs)¹³. Cells with number of
299 genes detected of less than 500 or over 15000, or UMI ratio of mitochondria encoded genes vs. all
300 genes over 0.15 were removed. Data normalization and scaling for each cell were achieved by
301 using Seurat global-scaling “LogNormalize” method. To avoid potential sample-to-sample
302 variation caused by technical variation at various experiment steps, we employed Seurat’s data
303 integration pipeline to merge all cochlea and utricle samples into a single Seurat object for
304 downstream analysis. Statistically significant principal components identified by Seurat’s
305 “RunPCA” function were used to define the dimensions for the UMAP nonlinear dimensionality
306 reduction analysis, which then visualized the cells on a 2D UMAP plot. Unsupervised clustering,
307 via Seurat’s “FindClusters” method (resolution = 0.6), identified groups of molecularly distinct
308 cells on the plot. Clusters in the UMAP plot were annotated based on cluster-specific genes
309 identified via Seurat’s “FindAllMarkers” (min.pct = 0.25, thresh.use = 0.25) function. The
310 expression of cluster marker genes as well as canonical cell type-specific genes were used to label
311 the cell type for each cluster.

312

313 **Mouse cochlea dissection for KLHDC7B quantitation:**

314 There were six biological replicates and three technical replicates of each sample. Cochlea
315 were dissected from B6.CAST-Cdh23Ahl^{+WT} mice ears. Both cochleae were pooled per mouse
316 from five female mice and one male mouse aged 11-28 weeks. Animals were sacrificed by carbon
317 dioxide inhalation followed by immediate removal of the organs in question, which were stored in
318 RNA later. Cochleae were pierced at the apex and oval window, then gently flushed with ~100 μ l

319 of RNA later, frozen on dry ice and stored at -80 degrees Celsius, while other organs were placed
320 in RNA later and frozen at -20 degrees Celsius until RNA extraction. The vestibular system was
321 included with the cochlea.

322

323 *RNA extraction and analysis:*

324 Tissue/Cells were homogenized in TRIzol, and chloroform was used for phase separation.
325 The aqueous phase, containing total RNA, was purified using MagMAX™ -96 for Microarrays
326 Total RNA Isolation Kit (Ambion by Life Technologies) according to manufacturer's
327 specifications. Genomic DNA was removed using RNase-Free DNase Set (Qiagen).

328 mRNA was reverse-transcribed into cDNA using SuperScript® VILO™ Master Mix
329 (Invitrogen by Life Technologies). cDNA was amplified with the SensiFAST Probe Lo-ROX
330 (Meridian) using the 12K Flex System (Applied Biosystems). An endogenous control gene was
331 used to normalize any cDNA input differences. The KLHDC7b primer/probe combination was
332 forward: GGTGGCCCTGGATGGAATG, reverse: TCTGTGCGTGGGTCATAGC, probe:
333 TTTATGCCATTGGTGGCGAGTGC. The Drosha housekeeping control spanned exons 34-35
334 and was acquired from ThermoFisher (Mm01310009_m1, catalogue number 4331182). Data is
335 reported as the comparative CT method using $\Delta\Delta CT$. The $\Delta Ct = Klhdc7b - Drosha$ (housekeeping
336 transcript), $\Delta\Delta Ct = \Delta Ct - \Delta Ct$ reference sample; Relative quantification (RQ) = $2^{-\Delta\Delta Ct}$.

337 **Supplementary References**

338

- 339 1. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
340 *Nature* **562**, 203–209 (2018).
- 341 2. Dewey, F. E. *et al.* Distribution and clinical impact of functional variants in 50,726 whole-
342 exome sequences from the DiscovEHR study. *Science* **354**, aaf6814 (2016).
- 343 3. Van Hout, C. V. *et al.* Exome sequencing and characterization of 49,960 individuals in the
344 UK Biobank. *Nature* **586**, 749–756 (2020).
- 345 4. Kosmicki, J. A. *et al.* Pan-ancestry exome-wide association analyses of COVID-19
346 outcomes in 586,157 individuals. *Am. J. Hum. Genet.* **108**, 1350–1355 (2021).
- 347 5. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
348 binary traits. *Nat. Genet.* (2021) doi:10.1038/s41588-021-00870-7.
- 349 6. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
350 genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 351 7. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
352 polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- 353 8. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-
354 wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
- 355 9. Staples, J. *et al.* PRIMUS: rapid reconstruction of pedigrees from genome-wide estimates of
356 identity by descent. *Am. J. Hum. Genet.* **95**, 553–564 (2014).
- 357 10. Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T.
358 Accurate, scalable and integrative haplotype estimation. *Nat. Commun.* **10**, 5436 (2019).

- 359 11. Zaitlen, N., Paşaniuc, B., Gur, T., Ziv, E. & Halperin, E. Leveraging genetic variability
360 across populations for the identification of causal variants. *Am. J. Hum. Genet.* **86**, 23–33
361 (2010).
- 362 12. Dobbyn, A. *et al.* Landscape of Conditional eQTL in Dorsolateral Prefrontal Cortex and
363 Co-localization with Schizophrenia GWAS. *Am. J. Hum. Genet.* **102**, 1169–1184 (2018).
- 364 13. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell
365 transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.*
366 **36**, 411–420 (2018).